MX370670B - Combinaciones que comprenden brexipiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central. - Google Patents

Combinaciones que comprenden brexipiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central.

Info

Publication number
MX370670B
MX370670B MX2013010796A MX2013010796A MX370670B MX 370670 B MX370670 B MX 370670B MX 2013010796 A MX2013010796 A MX 2013010796A MX 2013010796 A MX2013010796 A MX 2013010796A MX 370670 B MX370670 B MX 370670B
Authority
MX
Mexico
Prior art keywords
drug
salt
reuptake inhibitor
antidepressant
brexpiprazole
Prior art date
Application number
MX2013010796A
Other languages
English (en)
Other versions
MX2013010796A (es
Inventor
Hirose Tsuyoshi
Maeda Kenji
Kikuchi Tetsuro
Toda Masafumi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46045045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX370670(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2013010796A publication Critical patent/MX2013010796A/es
Publication of MX370670B publication Critical patent/MX370670B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un medicamento que tiene un mayor espectro de tratamiento, causando menores efectos colaterales y que es superior en tolerabilidad y seguridad, en comparación con agentes antipsicóticos típicos y agentes antipsicóticos atípicos conocidos. La presente invención se refiere a un medicamento que contiene (I) un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1H-quinolin-2- ona o una de sus sales y (II) al menos un fármaco seleccionado del grupo que consiste en un estabilizador del estado de ánimo, un inhibidor de la reabsorción de serotonina, un inhibidor de la reabsorción de norepinefrina, un inhibidor de la reabsorción de serotonina y norepinefrina, un antidepresivo noradrenérgico y serotonérgico específico, un fármaco antiansiedad, un antidepresivo tricíclico, un antidepresivo tetracíclico, un fármaco antipsicótico y un fármaco anti-ADHD, en combinación.
MX2013010796A 2011-04-05 2012-04-04 Combinaciones que comprenden brexipiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central. MX370670B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161471911P 2011-04-05 2011-04-05
US201161580540P 2011-12-27 2011-12-27
PCT/JP2012/059825 WO2012137971A1 (en) 2011-04-05 2012-04-04 Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder

Publications (2)

Publication Number Publication Date
MX2013010796A MX2013010796A (es) 2013-12-06
MX370670B true MX370670B (es) 2019-12-19

Family

ID=46045045

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013010796A MX370670B (es) 2011-04-05 2012-04-04 Combinaciones que comprenden brexipiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central.
MX2019015237A MX2019015237A (es) 2011-04-05 2013-09-20 Combinaciones que comprenden brexpiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019015237A MX2019015237A (es) 2011-04-05 2013-09-20 Combinaciones que comprenden brexpiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central.

Country Status (31)

Country Link
US (6) US20140120185A1 (es)
EP (4) EP2694043B1 (es)
JP (2) JP5992924B2 (es)
KR (1) KR101890450B1 (es)
CN (2) CN103547260B (es)
AR (1) AR085840A1 (es)
AU (1) AU2012240864B2 (es)
BR (1) BR112013025420B1 (es)
CA (1) CA2832157C (es)
CO (1) CO6801769A2 (es)
CY (1) CY1120567T1 (es)
DK (1) DK2694043T3 (es)
EA (1) EA035837B1 (es)
ES (1) ES2654851T3 (es)
HK (1) HK1246159A1 (es)
HR (1) HRP20180098T1 (es)
HU (1) HUE035542T2 (es)
IL (1) IL228669B (es)
JO (2) JOP20120083B1 (es)
LT (1) LT2694043T (es)
MX (2) MX370670B (es)
MY (1) MY166936A (es)
NZ (1) NZ615591A (es)
PL (1) PL2694043T3 (es)
PT (1) PT2694043T (es)
RS (1) RS56802B1 (es)
SG (2) SG193468A1 (es)
SI (1) SI2694043T1 (es)
TW (1) TWI636784B (es)
WO (1) WO2012137971A1 (es)
ZA (1) ZA201306981B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
AR088372A1 (es) * 2011-10-19 2014-05-28 Otsuka Pharma Co Ltd Solucion para administracion oral
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
TW201625252A (zh) 2014-04-22 2016-07-16 大塚製藥股份有限公司 藥物
US20170196846A1 (en) * 2014-06-06 2017-07-13 Rhodes Pharmaceuticals, L.P. Methods for treating attention deficit hyperactivity disorder with methylphenidate
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
CA3019351C (en) 2016-04-01 2023-09-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Regulatory device and associated method
US11123300B2 (en) 2016-08-16 2021-09-21 Hexal Ag Immediate release tablet of a benzothiophene compound
US20200093821A1 (en) 2016-08-16 2020-03-26 Hexal Ag Pharmaceutical Compositions of a Benzothiophene Compound
SG11201903770UA (en) * 2016-10-28 2019-05-30 H Lundbeck As Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3501506B1 (en) * 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
JP2019183095A (ja) * 2018-08-16 2019-10-24 株式会社Ｄｎｐファインケミカル 接着性粉体、接着性錠剤の製造方法、接着性錠剤、並びに該接着性粉体及び錠剤を用いた部材又は部品の製造方法
JP6831354B2 (ja) * 2018-08-16 2021-02-17 株式会社Ｄｎｐファインケミカル 接着性組成物からなる錠剤、その製造方法、及び該錠剤を用いた部材又は部品の製造方法
US20220031909A1 (en) * 2018-10-04 2022-02-03 École Polytechnique Fédérale De Lausanne (Epfl) Cross-Linkable Polymer, Hydrogel, and Method of Preparation Thereof
EP3870178A4 (en) * 2018-10-24 2022-08-03 Effector Therapeutics Inc. CRYSTALLINE FORMS OF MNK INHIBITORS
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN113322299A (zh) * 2021-05-28 2021-08-31 南昌大学 一种抑郁症和药物成瘾疾病的药物靶点识别方法
US20240009181A1 (en) * 2022-07-08 2024-01-11 Jason Eric Schiffman Method for the treatment and prophylaxis of substance-related and/or addictive disorders including substance/medication-induced depressive disorders, bipolar and related disorders, and anxiety disorders and compositions useful for the same
FR3142667A1 (fr) * 2022-12-01 2024-06-07 Capsum Composition solide non pulvérulente comprenant au moins 8% en poids d’agent(s) désintégrant
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US20040176466A1 (en) * 2001-08-08 2004-09-09 Allen Albert John Combination therapy for the treatment of neurological disorders
CN1989968B (zh) * 2002-12-27 2011-05-11 大塚制药株式会社 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂
WO2006004719A2 (en) * 2004-06-25 2006-01-12 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
CN101646432A (zh) * 2006-10-27 2010-02-10 詹森药业有限公司 治疗破坏性行为障碍的方法
JP2008189616A (ja) * 2007-02-07 2008-08-21 Mitsubishi Tanabe Pharma Corp 注意欠陥多動性障害の治療薬
JP2011136906A (ja) * 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物

Also Published As

Publication number Publication date
CA2832157A1 (en) 2012-10-11
WO2012137971A1 (en) 2012-10-11
SI2694043T1 (en) 2018-03-30
MY166936A (en) 2018-07-25
AR085840A1 (es) 2013-10-30
PL2694043T3 (pl) 2018-04-30
TW201311242A (zh) 2013-03-16
MX2013010796A (es) 2013-12-06
TWI636784B (zh) 2018-10-01
CN108042808B (zh) 2021-02-09
JP2014510023A (ja) 2014-04-24
ES2654851T3 (es) 2018-02-15
US20170100395A1 (en) 2017-04-13
SG193468A1 (en) 2013-10-30
CN108042808A (zh) 2018-05-18
US20240156811A1 (en) 2024-05-16
CA2832157C (en) 2023-06-27
RS56802B1 (sr) 2018-04-30
SG10201602326RA (en) 2016-04-28
EP4023223A1 (en) 2022-07-06
PT2694043T (pt) 2018-01-16
AU2012240864A1 (en) 2013-11-07
BR112013025420A2 (pt) 2016-12-27
EA035837B1 (ru) 2020-08-19
CN103547260A (zh) 2014-01-29
NZ615591A (en) 2016-02-26
JOP20210035A1 (ar) 2023-01-30
EP3626243A1 (en) 2020-03-25
HK1246159A1 (zh) 2018-09-07
JOP20120083B1 (ar) 2021-08-17
US20220000861A1 (en) 2022-01-06
JP5992924B2 (ja) 2016-09-14
KR101890450B1 (ko) 2018-08-21
HUE035542T2 (hu) 2018-05-02
US20180042923A1 (en) 2018-02-15
KR20140021648A (ko) 2014-02-20
IL228669A0 (en) 2013-12-31
BR112013025420B1 (pt) 2021-10-13
DK2694043T3 (en) 2018-01-15
IL228669B (en) 2020-04-30
US20180325894A1 (en) 2018-11-15
LT2694043T (lt) 2018-02-12
ZA201306981B (en) 2014-05-28
EP2694043B1 (en) 2017-11-01
CO6801769A2 (es) 2013-11-29
US20140120185A1 (en) 2014-05-01
EP3299018A1 (en) 2018-03-28
HRP20180098T1 (hr) 2018-03-23
JP2017031155A (ja) 2017-02-09
EP2694043A1 (en) 2014-02-12
CN103547260B (zh) 2019-08-13
EA201391450A1 (ru) 2014-03-31
CY1120567T1 (el) 2019-07-10
AU2012240864B2 (en) 2017-02-02
MX2019015237A (es) 2020-02-13

Similar Documents

Publication Publication Date Title
JOP20210035A1 (ar) توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
EA201171493A1 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
JO3421B1 (ar) طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
MA31358B1 (fr) Méthodes de traitement du cancer à l&#39;aide d&#39;inhibiteurs de pi3k alpha à base de pyridopyrimidinone
MX371279B (es) Agente profiláctico y/o terapéutico para síntomas conductuales y psicológicos asociados con la enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo.
DOP2009000232A (es) Metanoisoindoles y dionas de éstos como agentes anti-psicóticos.
IN2014DN09804A (es)
MA32784B1 (fr) Composes aryles substitues par heterocycle comme inhibiteurs de hif
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
SG195106A1 (en) Trpv4 antagonists
EA201200247A1 (ru) Новые азагетероциклические соединения
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
EA201171172A1 (ru) Применение в терапии производных хиназолиндиона
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
EA201170997A1 (ru) Производные индола в качестве противораковых агентов
UA104880C2 (uk) Заміщені тетрагідропіранспіропіролідинон і тетрагідропіранспіропіперидинон, спосіб їх одержання й застосування в лікувальних цілях
NI201000176A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.
EA201270556A1 (ru) Конденсированные тиазоло и оксазолопиримидиноны
DE602008002598D1 (en) Cyclohexylderivate
MX2011012596A (es) Metodos para incrementar os efectos de un inhibidor selectivo de la recaptacion de serotonina en los mamiferos.
MX2010004314A (es) Compuestos para inhibir la actividad de quinesina de la proteina quinesina del huso.

Legal Events

Date Code Title Description
FG Grant or registration